Keros Therapeutics Investor Relations Material

Keros Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel treatments aimed at addressing unmet medical needs in hematological, pulmonary, and cardiovascular disorders. By leveraging cutting-edge science, Keros is focused on creating therapies that have the potential to significantly improve patient outcomes. The company's research and development efforts are grounded in the transformative potential of TGF-β (transforming growth factor-beta) science. It is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.